Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Rigel Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small‑molecule therapies for hematologic disorders, cancer, and immune‑mediated diseases. The company’s business centers on advancing targeted therapies that address areas of unmet medical need, with revenue primarily derived from commercialized prescription medicines and collaboration arrangements.
Rigel’s primary revenue drivers are its commercial products, most notably TAVALISSE® (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor approved for adult patients with chronic immune thrombocytopenia (ITP), and REZLIDHIA® (olutasidenib), an oral IDH1 inhibitor approved for relapsed or refractory acute myeloid leukemia (AML). The company serves specialty physician markets, including hematologists and oncologists, and positions itself as a focused commercial-stage biotech with expertise in kinase inhibition and precision oncology. Rigel was founded in 1996 and evolved from a discovery‑oriented research company into a commercial-stage organization following regulatory approvals beginning in 2018.
Business Operations
Rigel operates through an integrated model encompassing research and development, regulatory approval, and commercialization. Its operations are organized around commercial products and clinical-stage development programs, with revenue generated from U.S. product sales and ex‑U.S. collaboration and licensing agreements. The company conducts clinical development internally while leveraging third parties for manufacturing and certain commercial activities.
Commercial operations are primarily U.S.-based, while international sales of TAVALISSE® are conducted through partnerships, most notably with Grifols S.A., which holds rights in multiple ex‑U.S. territories. Rigel controls a portfolio of proprietary small‑molecule compounds and associated intellectual property and maintains subsidiaries that support clinical, regulatory, and commercial activities. No material joint ventures beyond licensing and collaboration agreements are consistently disclosed across public filings.
Strategic Position & Investments
Rigel’s strategy emphasizes maximizing the value of its approved products while selectively investing in late‑stage and targeted oncology and hematology assets. A key strategic milestone was the acquisition of Forma Therapeutics Holdings, Inc. in 2022, which added REZLIDHIA® (olutasidenib) to Rigel’s commercial portfolio and expanded its presence in precision oncology.
The company continues to invest in lifecycle management for its marketed therapies and in earlier‑stage programs targeting signaling pathways implicated in immune and malignant diseases. Rigel’s strategic positioning reflects a transition toward a multi‑asset commercial biopharmaceutical company, balancing near‑term revenue generation with disciplined pipeline investment. Where public disclosures vary on the prioritization or timing of specific pipeline programs, data is inconclusive based on available public sources.
Geographic Footprint
Rigel Pharmaceuticals is headquartered in South San Francisco, California, and its core operations are concentrated in the United States. The U.S. represents the company’s primary commercial market, particularly for TAVALISSE® and REZLIDHIA®, supported by a specialty sales infrastructure targeting hematology and oncology practices.
Internationally, Rigel maintains a commercial and investment presence through licensing and distribution partnerships across Europe, Asia, and other global regions. These partnerships enable market access without the need for large-scale direct infrastructure, extending Rigel’s operational influence beyond North America while maintaining a capital‑efficient footprint.
Leadership & Governance
Rigel is led by an executive team with experience in biotechnology research, drug development, and commercial operations. The company’s leadership emphasizes scientific rigor, disciplined capital allocation, and a focused approach to building value through targeted therapies in hematology and oncology.
Key executives include:
- Raul Rodriguez, M.D. – President and Chief Executive Officer
- Jim Schoeneck – Executive Vice President and Chief Financial Officer
- Patricia Conkling, M.D. – Chief Medical Officer
- Andrew J. Sellers – Chief Legal Officer and Corporate Secretary
The leadership team operates under governance practices consistent with U.S. public biotechnology companies and is overseen by an independent board of directors, as disclosed in SEC filings and company governance documents.